Clinical Trial Update: Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the safety and preliminary efficacy of EXG202 gene therapy for wet age-related macular degeneration. The study status is n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• EXG202 (EXG202)

Snippet

Sponsor: Guangzhou Jiayin Biotech Ltd | Conditions: Wet Age-related Macular Degeneration | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING